Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

PT

PLUS THERAPEUTICS, Inc.

$3.87

0 (0%)

Last traded Jul 31, 2026. This price is not current.

D 26Pipeline Score Richly Valued Biotech · Clinical
Market Cap
45.36 M
EPS
-2.49
P/E Ratio
-
Value Trade
565.11 K
18.31 %
Week
-5.99 %
1 Month
-10.8 %
3 Month
-46.43 %
6 Month
-99.21 %
5 Year
-100 %
All Time
Cash Data

  • Cash Position

    -

  • Monthly Burn

    -

  • Runway

    -

Overview
Volume
96.53 K
52 Week Range
2.90 - 23.43
% held by Insiders
0.99 %
% held by Institutions
15.75 %
Enterprise Value
30.97 M
Total Shares
138.88 M
Short %
9.45 %
Float Shares
125.41 M
Company Description
HQ: 4200 MARATHON BLVD., AUSTIN, T...
Employees:28
https://www.plustherapeutics.c...

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data

Catalyst Timeline

Dated clinical, regulatory & corporate events for PLUS THERAPEUTICS, Inc.

652Total events
15Upcoming
97Tier-1 (high impact)
2013 – 2027Coverage

Upcoming catalysts 2

TBD
T2Equity Offering
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
REYOBIQFiled

Event history 2

TBD
◆Poster PresentationPresentation
Subscribe to view catalyst details
TBD
◆Poster PresentationCNSideApprovedPresentation
Subscribe to view catalyst details
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2025-08-14
REYOBIQ™ (rhenium Re186obisbemeda)
phase 1 data readout
Phase 1
—
–
–
–
2025-08-14
REYOBIQ™ (rhenium Re186obisbemeda)
phase 1 data readout
Phase 1
—
–
–
–
2025-08-14
REYOBIQ™ (rhenium Re186obisbemeda)
phase 1 data readout
Phase 1
—
–
–
–
Unlock 3 more historical catalysts
Drug Pipeline Intelligence
D26
Pipeline Score
$5M
Pipeline Value
Richly Valued
Valuation Signal
6
Drugs Scored
0.1x
rNPV / MCap
Top 27%
Micro Cap
(rank 682 of 933)
Percentile Rank
PLUS THERAPEUTICS, Inc. faces pipeline headwinds (26/100), with $407M risk-adjusted pipeline value, led by Rhenium-186 Nanoliposome in Ependymoma (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Rhenium-186 Nanoliposome
Small molecule		EpendymomaPhase 1NCT070616265% $190M NOT YET_RECRUITING 56 AVERAGE D (30) Mar 1, 2027MODERATE_RISKJul 11, 2025
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
REYOBIQ
Orphan
leptomeningeal metastases
Phase 1
2026-05-08

median overall survival: approximately 9 months; historical survival: approximately 2–6 months; target to off target ratio: exceeding 100:1

Read More

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

Read More
REYOBIQ
Orphan
leptomeningeal metastases
Phase 1
2026-05-08

median overall survival: approximately 9 months; historical survival: approximately 2–6 months; target to off target ratio: exceeding 100:1

Read More

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

Read More
REYOBIQ
Orphan
leptomeningeal metastases
Phase 1
2026-05-08

median overall survival: approximately 9 months; historical survival: approximately 2–6 months; target to off target ratio: exceeding 100:1

Read More

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in PSTV
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
PSTV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How PSTV ranks across every disease it competes in
Competitive Position is a premium feature
See how PSTV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial